Autolus Therapeutics plc
For the period ended Dec 31, 2023. Filed Mar 21, 2024.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2023 · Filed Mar 21, 2024
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Signatures
Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, as amended, the Registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
| AUTOLUS THERAPEUTICS PLC | ||
| Date: March 21, 2024 | By: | /s/ Christian Itin, Ph.D. |
|---|---|---|
| Christian Itin, Ph.D. | ||
| Chief Executive Officer | ||
POWER OF ATTORNEY
We, the undersigned officers and directors of Autolus Therapeutics plc, hereby severally constitute and appoint Christian Itin and Alex Driggs our true and lawful attorneys with full power to any of them, and to each of them singly, to sign for us and in our names in the capacities indicated below to sign any and all amendments to this Annual Report on Form 10-K, and to file the same, with exhibits thereto and other documents in connection therewith, with the U.S. Securities Exchange Commission, granting unto said attorneys-in-fact and agents, and each of them, full power and authority to do and perform each and every act and thing requisite and necessary to be done therewith, as fully to all intents and purposes as he or she might or could do in person, hereby ratifying and confirming all that said attorneys-in-fact and agents, and either of them, his or her substitute or substitutes, may lawfully do or cause to be done by virtue hereof.
Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, this Annual Report on Form 10-K has been signed below by the following persons on behalf of the Registrant in the capacities and on the dates indicated.
| Signature | Title | Date |
|---|---|---|
| /s/ Christian Itin, Ph.D. | Chief Executive Officer and Director | March 21, 2024 |
| Christian Itin, Ph.D. | (Principal Executive Officer) | |
| /s/ Robert Dolski | Chief Financial Officer | March 21, 2024 |
| Robert Dolski | (Principal Financial Officer) | |
| /s/ Andrew Mercieca | Vice President, Finance | March 21, 2024 |
| Andrew Mercieca | (Principal Accounting Officer) | |
| /s/ John Johnson | Chairman of the Board of Directors | March 21, 2024 |
| John Johnson | ||
| /s/ Joseph Anderson, Ph.D. | Director | March 21, 2024 |
| Joseph Anderson, Ph.D. | ||
| /s/ Robert Azelby | Director | March 21, 2024 |
| Robert Azelby | ||
| /s/ Linda Bain | Director | March 21, 2024 |
| Linda Bain | ||
| /s/ John Berriman | Director | March 21, 2024 |
| John Berriman | ||
| /s/ Cynthia Butitta | Director | March 21, 2024 |
| Cynthia Butitta | ||
| /s/ Robert Iannone, M.D., M.S.C.E. | Director | March 21, 2024 |
| Robert Iannone, M.D., M.S.C.E | ||
| /s/ Elisabeth Leiderman, M.D. | Director | March 21, 2024 |
| Elisabeth Leiderman, M.D. | ||
| /s/ Martin Murphy, Ph.D. | Director | March 21, 2024 |
| Martin Murphy, Ph.D. | ||
| /s/ William Young | Director | March 21, 2024 |
| William Young | ||
INDEX TO CONSOLIDATED FINANCIAL STATEMENTS
| Report of Independent Registered Public Accounting Firm (PCAOB ID: 01438) | F-2 |
|---|---|
| Consolidated Balance Sheets as of December 31, 2023 and 2022 | F-4 |
| Consolidated Statements of Operations and Comprehensive Loss for the years ended December 31, 2023, 2022 and 2021 | F-5 |
| Consolidated Statements of Shareholders’ Equity for the years ended December 31, 2023, 2022 and 2021 | F-6 |
| Consolidated Statements of Cash Flows for the years ended December 31, 2023, 2022 and 2021 | F-7 |
| Notes to Consolidated Financial Statements | F-9 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.